Sphera Funds Management
Latest statistics and disclosures from Sphera Funds Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TEVA, BIIB, MLYS, TSEM, CYTK, and represent 24.58% of Sphera Funds Management's stock portfolio.
- Added to shares of these 10 stocks: BIIB (+$23M), INSM (+$13M), TEVA (+$12M), BMRN (+$11M), RYTM (+$8.9M), LRCX (+$8.0M), AMAT (+$8.0M), IDYA (+$7.3M), NVCT (+$7.0M), HRMY (+$6.4M).
- Started 24 new stock positions in CABA, AMAT, ALNY, VST, PRQR, INSM, LRMR, TSHA, IKT, AVTX. RYTM, IMMX, TRAX, CEG, TRAW, CLOU, BBOT, LRCX, NVCT, TLN, IDYA, PRAX, ABVX, HRMY.
- Reduced shares in these 10 stocks: CRIS (-$20M), NVMI (-$15M), TSEM (-$9.8M), , CLBT (-$8.7M), Apellis Pharmaceuticals (-$8.6M), PANW (-$8.5M), , XBI (-$7.9M), RARE (-$7.4M).
- Sold out of its positions in AMZN, FOLD, Apellis Pharmaceuticals, AAOI, Ascendis Pharma A S, BMY, ENPH, FHTX, IBIT, NICE. OLMA, PANW, DTIL, SEDG, Soleno Therapeutics, CAMT, CLBT, ZIM.
- Sphera Funds Management was a net buyer of stock by $31M.
- Sphera Funds Management has $767M in assets under management (AUM), dropping by 21.73%.
- Central Index Key (CIK): 0001496201
Tip: Access up to 7 years of quarterly data
Positions held by Sphera Funds Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sphera Funds Management
Sphera Funds Management holds 101 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 6.6 | $51M | +31% | 1.5M | 33.88 |
|
| Biogen Idec (BIIB) | 5.5 | $43M | +112% | 197k | 216.06 |
|
| Mineralys Therapeutics (MLYS) | 5.2 | $40M | +9% | 1.5M | 26.98 |
|
| Tower Semiconductor Shs New (TSEM) | 3.7 | $28M | -25% | 108k | 260.64 |
|
| Cytokinetics Com New (CYTK) | 3.6 | $27M | +6% | 320k | 85.19 |
|
| Spdr Series Trust St Str Sp Biot Put Option (XBI) | 3.1 | $24M | -25% | 150k | 158.25 |
|
| Syndax Pharmaceuticals (SNDX) | 2.9 | $22M | +40% | 1.0M | 21.86 |
|
| Ultragenyx Pharmaceutical (RARE) | 2.6 | $20M | -27% | 589k | 33.39 |
|
| BioMarin Pharmaceutical (BMRN) | 2.5 | $19M | +134% | 329k | 57.22 |
|
| Bridgebio Pharma (BBIO) | 2.4 | $18M | 245k | 74.48 |
|
|
| Cogent Biosciences (COGT) | 2.3 | $18M | +10% | 459k | 38.70 |
|
| NOVA MEASURING Instruments L (NVMI) | 1.8 | $14M | -52% | 25k | 542.94 |
|
| Insmed Com Par $.01 (INSM) | 1.7 | $13M | NEW | 119k | 106.62 |
|
| Maze Therapeatics (MAZE) | 1.6 | $13M | +83% | 418k | 29.84 |
|
| Astrazeneca Ord (AZN) | 1.5 | $12M | 63k | 189.62 |
|
|
| Sanofi Sa Sponsored Adr (SNY) | 1.5 | $12M | 270k | 42.66 |
|
|
| Cybin Com New (HELP) | 1.4 | $11M | +64% | 1.6M | 6.61 |
|
| Eli Lilly & Co. (LLY) | 1.3 | $9.6M | -11% | 8.0k | 1199.43 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.2 | $9.4M | +92% | 17k | 536.95 |
|
| Trevi Therapeutics (TRVI) | 1.2 | $9.3M | -13% | 499k | 18.65 |
|
| Oric Pharmaceuticals (ORIC) | 1.2 | $9.2M | +58% | 853k | 10.83 |
|
| ACADIA Pharmaceuticals (ACAD) | 1.2 | $9.0M | +39% | 357k | 25.30 |
|
| Celldex Therapeutics Com New (CLDX) | 1.2 | $9.0M | 241k | 37.21 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $8.9M | NEW | 80k | 111.03 |
|
| Lam Research Corp Com New (LRCX) | 1.0 | $8.0M | NEW | 19k | 433.33 |
|
| Applied Materials (AMAT) | 1.0 | $8.0M | NEW | 11k | 723.00 |
|
| Tango Therapeutics (TNGX) | 1.0 | $7.9M | -25% | 254k | 31.26 |
|
| Novartis Sponsored Adr (NVS) | 1.0 | $7.8M | +35% | 50k | 156.66 |
|
| Solaredge Technologies Note 2.250% 7/0 | 1.0 | $7.7M | 4.0M | 1.94 |
|
|
| Vor Biopharma Com New (VOR) | 1.0 | $7.7M | +29% | 416k | 18.41 |
|
| Abbvie (ABBV) | 1.0 | $7.6M | 30k | 251.64 |
|
|
| Merck & Co (MRK) | 1.0 | $7.5M | +20% | 59k | 128.50 |
|
| Johnson & Johnson (JNJ) | 1.0 | $7.3M | 29k | 253.97 |
|
|
| Ideaya Biosciences (IDYA) | 1.0 | $7.3M | NEW | 196k | 37.27 |
|
| Immatics SHS (IMTX) | 1.0 | $7.3M | +3% | 720k | 10.13 |
|
| Nuvectis Pharma (NVCT) | 0.9 | $7.0M | NEW | 383k | 18.39 |
|
| Pfizer (PFE) | 0.9 | $6.9M | +53% | 286k | 24.08 |
|
| Harmony Biosciences Hldgs In (HRMY) | 0.8 | $6.4M | NEW | 177k | 36.41 |
|
| Xenon Pharmaceuticals (XENE) | 0.8 | $6.3M | -17% | 105k | 60.36 |
|
| Eliem Therapeutics (CLYM) | 0.8 | $6.3M | +15% | 484k | 13.04 |
|
| Zenas Biopharma (ZBIO) | 0.8 | $5.9M | +7% | 231k | 25.38 |
|
| Novo-nordisk A S Adr (NVO) | 0.8 | $5.8M | 121k | 47.94 |
|
|
| Enliven Therapeutics (ELVN) | 0.7 | $5.7M | -26% | 113k | 50.75 |
|
| Prelude Therapeutics (PRLD) | 0.7 | $5.4M | +82% | 1.0M | 5.33 |
|
| GSK Sponsored Adr (GSK) | 0.7 | $5.3M | -16% | 102k | 52.42 |
|
| Forte Biosciences Com New (FBRX) | 0.7 | $5.3M | +34% | 250k | 21.25 |
|
| Bioage Labs (BIOA) | 0.7 | $5.2M | +146% | 214k | 24.51 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.7 | $5.2M | 94k | 55.00 |
|
|
| Satellos Bioscience (MSLE) | 0.7 | $5.1M | +33% | 653k | 7.78 |
|
| Palisade Bio (PALI) | 0.6 | $4.7M | +30% | 2.3M | 2.09 |
|
| Eledon Pharmaceuticals (ELDN) | 0.6 | $4.7M | -32% | 1.2M | 3.94 |
|
| Vistra Energy (VST) | 0.6 | $4.7M | NEW | 30k | 158.63 |
|
| Talen Energy Corp (TLN) | 0.6 | $4.7M | NEW | 12k | 384.26 |
|
| Savara (SVRA) | 0.6 | $4.7M | +2% | 756k | 6.16 |
|
| Disc Medicine (IRON) | 0.6 | $4.6M | +18% | 64k | 73.14 |
|
| Global X Fds Cloud Computng (CLOU) | 0.6 | $4.5M | NEW | 196k | 22.74 |
|
| Dyne Therapeutics (DYN) | 0.6 | $4.4M | +24% | 200k | 22.21 |
|
| Relay Therapeutics (RLAY) | 0.6 | $4.4M | -42% | 234k | 18.71 |
|
| Avalo Therapeutics Com New (AVTX) | 0.6 | $4.3M | NEW | 232k | 18.48 |
|
| Promis Neurosciences Com Shs (PMN) | 0.6 | $4.3M | 326k | 13.16 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.6 | $4.2M | -51% | 422k | 10.00 |
|
| Revolution Medicines (RVMD) | 0.5 | $4.2M | -59% | 22k | 187.28 |
|
| Praxis Precision Medicines I Com New Call Option (PRAX) | 0.5 | $4.2M | NEW | 13k | 334.79 |
|
| Cabaletta Bio (CABA) | 0.5 | $4.1M | NEW | 1.3M | 3.11 |
|
| Generate Biomedicines Com Shs (GENB) | 0.5 | $4.1M | +32% | 245k | 16.87 |
|
| Ishares Tr 20 Yr Tr Bd Etf Call Option (TLT) | 0.5 | $4.1M | 47k | 86.42 |
|
|
| Mediwound Shs New (MDWD) | 0.5 | $4.0M | 273k | 14.70 |
|
|
| Alpha Cognition Com New (ACOG) | 0.5 | $3.9M | -3% | 546k | 7.22 |
|
| Wave Life Sciences SHS (WVE) | 0.5 | $3.7M | +16% | 638k | 5.81 |
|
| Corvus Pharmaceuticals (CRVS) | 0.5 | $3.7M | 245k | 14.94 |
|
|
| Ovid Therapeutics (OVID) | 0.5 | $3.6M | -16% | 1.4M | 2.69 |
|
| Tenax Therapeutics Com New (TENX) | 0.5 | $3.6M | +82% | 248k | 14.55 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.5 | $3.5M | NEW | 461k | 7.62 |
|
| Cytomx Therapeutics (CTMX) | 0.4 | $3.3M | +299% | 879k | 3.75 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.4 | $3.3M | NEW | 1.8M | 1.86 |
|
| Alnylam Pharmaceuticals (ALNY) | 0.4 | $3.3M | NEW | 11k | 301.03 |
|
| Kura Oncology (KURA) | 0.4 | $3.2M | 295k | 10.97 |
|
|
| Kodiak Sciences (KOD) | 0.4 | $3.2M | -28% | 82k | 38.96 |
|
| Ormat Technologies (ORA) | 0.4 | $3.1M | -58% | 28k | 108.90 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.4 | $3.0M | +5% | 184k | 16.39 |
|
| Larimar Therapeutics (LRMR) | 0.4 | $2.8M | NEW | 926k | 3.05 |
|
| Immix Biopharma (IMMX) | 0.4 | $2.8M | NEW | 270k | 10.31 |
|
| Amgen (AMGN) | 0.4 | $2.7M | 7.5k | 362.12 |
|
|
| Abivax Sa Sponsored Ads Put Option (ABVX) | 0.3 | $2.7M | NEW | 20k | 133.26 |
|
| Biohaven (BHVN) | 0.3 | $2.4M | -72% | 164k | 14.88 |
|
| Constellation Energy (CEG) | 0.3 | $2.4M | NEW | 9.9k | 248.37 |
|
| Verastem Com New (VSTM) | 0.3 | $2.4M | +84% | 633k | 3.82 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.2 | $1.7M | NEW | 250k | 6.81 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.2 | $1.5M | -43% | 29k | 53.67 |
|
| Upstream Bio (UPB) | 0.2 | $1.5M | -38% | 220k | 6.92 |
|
| Voyager Therapeutics (VYGR) | 0.2 | $1.5M | -8% | 428k | 3.50 |
|
| Organogenesis Hldgs (ORGO) | 0.2 | $1.3M | 550k | 2.43 |
|
|
| Inhibikase Therapeutics Com New (IKT) | 0.2 | $1.3M | NEW | 649k | 2.03 |
|
| Curis (CRIS) | 0.1 | $1.0M | -95% | 99k | 10.44 |
|
| Shattuck Labs (STTK) | 0.1 | $600k | -69% | 87k | 6.94 |
|
| First Tracks Biotherapeutics Ord Shs (TRAX) | 0.1 | $561k | NEW | 28k | 20.12 |
|
| Skye Bioscience Com New (SKYE) | 0.1 | $471k | 679k | 0.69 |
|
|
| Traws Pharma Com New (TRAW) | 0.0 | $336k | NEW | 399k | 0.84 |
|
| Evommune Com Shs (EVMN) | 0.0 | $301k | -71% | 23k | 13.29 |
|
| Werewolf Therapeutics (HOWL) | 0.0 | $226k | 627k | 0.36 |
|
|
| Aprea Therapeutics Com New (APRE) | 0.0 | $217k | 270k | 0.80 |
|
Past Filings by Sphera Funds Management
SEC 13F filings are viewable for Sphera Funds Management going back to 2013
- Sphera Funds Management 2026 Q2 filed Aug. 14, 2026
- Sphera Funds Management 2026 Q1 filed May 15, 2026
- Sphera Funds Management 2025 Q4 filed Feb. 17, 2026
- Sphera Funds Management 2025 Q3 filed Nov. 14, 2025
- Sphera Funds Management 2025 Q2 filed Aug. 14, 2025
- Sphera Funds Management 2025 Q1 filed May 15, 2025
- Sphera Funds Management 2024 Q4 filed Feb. 14, 2025
- Sphera Funds Management 2024 Q3 filed Nov. 14, 2024
- Sphera Funds Management 2024 Q2 filed Aug. 14, 2024
- Sphera Funds Management 2024 Q1 filed May 15, 2024
- Sphera Funds Management 2023 Q4 restated filed Feb. 15, 2024
- Sphera Funds Management 2023 Q4 filed Feb. 14, 2024
- Sphera Funds Management 2023 Q3 filed Nov. 14, 2023
- Sphera Funds Management 2023 Q2 filed Aug. 14, 2023
- Sphera Funds Management 2023 Q1 filed May 15, 2023
- Sphera Funds Management 2022 Q4 filed Feb. 14, 2023